摘要
目的:观察干扰素联合孟鲁司特、维生素D治疗喘息性支气管炎的疗效。方法:选取2016年3月至2018年9月我院儿科收治的96例喘息性支气管炎患儿,按照随机数字表分为观察组、对照组各48例,对照组给予孟鲁司特联合维生素D治疗,观察组在此基础上加以干扰素治疗,以7d为一个疗程,一个疗程结束后分析两组疗效、免疫功能,并观察药物不良反应、患儿6个月内复发率。结果:观察组喘息、咳嗽、肺部哮鸣音各症状缓解时间及住院时间均显著低于对照组(P<0.05);两组临床疗效比较差异有统计学意义(P<0.05),且观察组总有效率显著高于对照组(92.00%&76.00%)(P<0.05);治疗后,两组IgA、CD4^+、CD4^+/CD8^+均显著高于治疗前(P<0.05),IgE、CD8^+均显著低于治疗前(P<0.05),且观察组IgA、CD4^+、CD4^+/CD8^+升高幅度、IgE、CD8^+降低幅度大于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(8.33%&6.25%)(P>0.05),6个月内,观察组复发率显著低于对照组(4.17%&18.72%)(P<0.05)。结论:干扰素联合孟鲁司特、维生素D治疗喘息性支气管炎,可有效促进患儿症状缓解、提高临床疗效、改善患儿免疫功能、降低复发率,且安全性好,有临床应用价值。
Objective:To observe the efficacy of interferon combined with montelukast and vitamin D in the treatment of asthmatic bronchitis.Methods:A total of 96 children patients with asthmatic bronchitis admitted to pediatric department of our hospital from March 2016 to September 2018 were selected and divided into observation group and control group according to the random number table method,with 48 cases in each group.Control group was given montelukast combined with vitamin D,and observation group was given interferon on this basis,and 7d was taken as one course of treatment.The efficacy and immune function were analyzed in the two groups after the end of one course of treatment,and the adverse drug reactions and recurrence rate within 6 months were observed.Results:The remission times of symptoms of wheezing,cough and lung wheezing rale and hospital stay in observation group were significantly lower than those in control group(P<0.05).There was a statistically significant difference in the clinical efficacy between the two groups(P<0.05),and the total effective rate in observation group was significantly higher than that in control group(92.00%&76.00%)(P<0.05).After treatment,the levels of IgA,CD4^+and CD4^+/CD8^+in the two groups were significantly higher than those before treatment(P<0.05)while the levels of IgE and CD8^+were significantly lower than those before treatment(P<0.05),and the increases of IgA,CD4^+and CD4^+/CD8^+and decreases of IgE and CD8^+in observation group were greater than those in control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(8.33%&6.25%)(P>0.05).Within 6 months,the recurrence rate in observation group was significantly lower than that in control group(4.17%&18.72%)(P<0.05).Conclusion:Interferon combined with montelukast and vitamin D in the treatment of asthmatic bronchitis can effectively alleviate symptoms,improve clinical efficacy,improve immune function and reduce the recurrence rate of children with asthmatic b
作者
孙萌
谷名晓
SUN Meng;GU Mingxiao(Qingdao Women's and Children's Hospital,Shandong Qingdao 266000,China)
出处
《河北医学》
CAS
2019年第11期1805-1809,共5页
Hebei Medicine
基金
山东省医药卫生科技发展计划项目,(编号:2016WS0326)
